Were the Beta Bionics (BBNX) CFO’s share sales under a Rule 10b5-1 plan?

Yes. The filing states that the reported share sales were made pursuant to a Rule 10b5-1 trading plan adopted on May 15, 2025. Such plans pre-schedule trades, indicating these transactions were arranged in advance rather than timed discretionarily.

CFO trades 10,000 Beta Bionics (BBNX) shares under Rule 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

4/A

Rhea-AI Filing Summary

Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported an amended insider transaction combining option exercises and share sales. On June 26 and June 29, 2026, he exercised options for a total of 10,000 shares of common stock at a conversion price of $5.10 per share and sold 10,000 shares in open-market transactions.

The weighted average sale prices were $17.046782 on June 26 and $17.0304 on June 29, with trades executed between $17.00 and about $17.12. Following these transactions, he held 166,053 shares of common stock directly. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on May 15, 2025. This amendment corrects the number of shares subject to the June 26, 2026 option exercise and the number of securities beneficially owned after the transactions.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($170,387)

Net Sell 6 txns

Insider Feider Stephen

Role Chief Financial Officer

Sold 10,000 shs ($170K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	4,896	$0.00	--
Exercise	Common Stock	4,896	$5.10	$25K
Sale	Common Stock	4,896	$17.0304	$83K
Exercise	Employee Stock Option (right to buy)	5,104	$0.00	--
Exercise	Common Stock	5,104	$5.10	$26K
Sale	Common Stock	5,104	$17.0467	$87K

Holdings After Transaction: Employee Stock Option (right to buy) — 39,695 shares (Direct, null); Common Stock — 170,949 shares (Direct, null)

Footnotes (1)

This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. The weighted average sale price for the transaction reported was $17.046782 and the range of prices were between $17 and $17.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $17.0304 and the range of prices were between $17 and $17.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.

Key Figures

Shares sold: 10,000 shares Option exercise price: $5.10 per share Weighted average sale price 6/26: $17.046782 per share +2 more

5 metrics

Shares sold 10,000 shares Total common stock sold on June 26 and 29, 2026

Option exercise price $5.10 per share Conversion price for 10,000 shares of common stock

Weighted average sale price 6/26 $17.046782 per share Common stock sold June 26, 2026; range $17.00–$17.12

Weighted average sale price 6/29 $17.0304 per share Common stock sold June 29, 2026; range $17.00–$17.08

Post-transaction holdings 166,053 shares Common stock directly owned after reported transactions

Key Terms

Rule 10b5-1 Plan, weighted average sale price, Employee Stock Option (right to buy), beneficially owned, +1 more

5 terms

Rule 10b5-1 Plan regulatory

"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $17.046782 and the range of prices were between $17 and $17.12."

Employee Stock Option (right to buy) financial

"Employee Stock Option (right to buy) with a conversion or exercise price of $5.1000."

beneficially owned regulatory

"to correct the number of securities beneficially owned following the reported transactions."

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Form 4 regulatory

"This Form 4 is being amended to correct the number of shares subject to the option exercise."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 06:45 PM Accepted by SEC EDGAR 07/02/2026 - 06:44 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feider Stephen

(Last)

(First)

(Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE

CALIFORNIA

92618

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/30/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/26/2026		M		5,104⁽¹⁾	A	$5.1	171,157⁽¹⁾	D
Common Stock	06/26/2026		S⁽²⁾		5,104	D	$17.0467⁽³⁾	166,053⁽¹⁾	D
Common Stock	06/29/2026		M		4,896	A	$5.1	170,949⁽¹⁾	D
Common Stock	06/29/2026		S⁽²⁾		4,896	D	$17.0304⁽⁴⁾	166,053⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$5.1	06/26/2026		M			5,104⁽¹⁾	⁽⁵⁾	09/13/2033	Common Stock	5,104⁽¹⁾	$0	44,591⁽¹⁾	D
Employee Stock Option (right to buy)	$5.1	06/29/2026		M			4,896	⁽⁵⁾	09/13/2033	Common Stock	4,896	$0	39,695⁽¹⁾	D

Explanation of Responses:

1. This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions.

2. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.

3. The weighted average sale price for the transaction reported was $17.046782 and the range of prices were between $17 and $17.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

4. The weighted average sale price for the transaction reported was $17.0304 and the range of prices were between $17 and $17.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

5. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.

	/s/ Stephen Feider	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Beta Bionics (BBNX) CFO Stephen Feider report?

Stephen Feider reported an amended insider transaction involving option exercises and open-market sales of 10,000 Beta Bionics common shares. The filing corrects the June 26, 2026 option exercise amount and the resulting number of shares beneficially owned after the transactions.

How many Beta Bionics (BBNX) shares did the CFO sell and at what prices?

The CFO sold 10,000 common shares in total, split across June 26 and June 29, 2026. Weighted average sale prices were about $17.046782 and $17.0304, with trades occurring in a narrow range between $17.00 and roughly $17.12 per share.

What options did the Beta Bionics (BBNX) CFO exercise in this Form 4/A?

He exercised employee stock options covering 10,000 shares of Beta Bionics common stock at a conversion price of $5.10 per share. These option exercises occurred on June 26 and June 29, 2026, and were linked to the reported open-market sales.

How many Beta Bionics (BBNX) shares does the CFO own after these transactions?

After the reported transactions, the CFO directly owns 166,053 shares of Beta Bionics common stock. This updated balance reflects the combined effect of exercising options for 10,000 shares and selling 10,000 shares in the open market during June 2026.

Why was this Beta Bionics (BBNX) Form 4 amended?

The Form 4 was amended to correct the number of shares subject to the option exercise on June 26, 2026, and to adjust the reported number of securities beneficially owned after the transactions. The amendment refines previously reported figures without changing the overall transaction pattern.